BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

NCT01870505 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Metastatic or Locally-advanced Unresectable Breast Cancer

Interventions

DRUG: BYL719
DRUG: Letrozole
DRUG: Exemestane

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]